Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Receptor Activator for Nuclear Factor-kappa B Ligand (RANKL)
- Target
- RANKL
- Molecular classification
- Tumor necrosis factor (TNF) cytokine family, Type II transmembrane protein
01
Overview
Receptor Activator for Nuclear Factor-kappa B Ligand (RANKL) is a type II transmembrane protein belonging to the TNF cytokine family. It is a key regulator of osteoclast differentiation, activation, and survival, playing a critical role in bone remodeling and resorption. RANKL is also involved in immune regulation, hematopoiesis, and the formation of specialized immune microenvironments. Its dysregulation is implicated in various diseases, including osteoporosis, rheumatoid arthritis, and cancer with bone metastasis, making it a therapeutic target.
- Other names
- TNFSF11Tumor necrosis factor ligand superfamily member 11Osteoclast differentiation factor (ODF)TRANCE
02
Mechanism of action
Monoclonal antibody against human RANKL, inhibiting RANKL-RANK interaction.
03
Biological functions
OsteoclastogenesisBone remodelingImmune regulationHematopoiesisDendritic cell maturation/survivalMacrophage niche formation
04
Disease associations
OsteoporosisRheumatoid arthritisBone metastasisCancerInflammatory arthritis
05
Safety considerations
Potential for over-suppression of bone turnoverIncreased risk of infectionsHypocalcemia
06
Interacting drugs
Denosumab
07
Biomarkers
Disease progression/severity in osteoporosisDisease progression/severity in rheumatoid arthritisDisease progression/severity in cancers with osseous metastasesPotential predictor of response/resistance to some immunotherapies
Beyond the preview
Go deeper on Receptor Activator for Nuclear Factor-kappa B Ligand (RANKL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Receptor Activator for Nuclear Factor-kappa B Ligand (RANKL).